Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF AUGUST 02, 2014 FBO #4634
DOCUMENT

Q -- Cardio MRI Research Study - Attachment

Notice Date

7/31/2014
 

Notice Type

Attachment
 

NAICS

541712 — Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
 

Contracting Office

Department of Veterans Affairs;Birmingham VA Medical Center;700 South 19th Street;Birmingham AL 35233
 

ZIP Code

35233
 

Solicitation Number

VA24714I1255
 

Response Due

8/6/2014
 

Archive Date

9/5/2014
 

Point of Contact

Connie Ganier
 

E-Mail Address

3-8101
 

Small Business Set-Aside

N/A
 

Description

521-14-4-4195-0200 Statement of Work for Cardiovascular MRI Brain atrophy is the radiological measurement which correlates most strongly with disability in progressive MS. Longitudinal research has revealed similar rates of atrophy regardless of clinical subtype, suggesting that this final common indicator of axonal loss is evident in all stages and subtypes of MS. In other words, brain atrophy indicates axonal and neuronal loss due to inflammatory activity as well as neurodegenerative processes. Thus, measuring atrophy takes into account both the inflammatory and neurodegenerative processes at work in progressive MS. Although several methods of measuring brain volume are available, in MS the BPF is most widely used and correlates well with disability outcomes". Methods. MRI will be performed on a Philips Achieva 3T head-only scanner. All scans will be performed on the same machine according to the 2003 Consortium of Multiple Sclerosis Centers imaging guidelines (below): 1.Anatomic scouts. These scouts will be used for scan planning (Total scan time = 20 s) 2.Dark Fluid/FLAIR-1 (fluid attenuating inversion recovery).Sagittal plane, Field of View = 230 mm2, Matrix = 256 x 256, TRITE/TI = 10,000199/2150 ms, 3 mm slice thickness, no inter-slice gap, 40 slices, Voxel size = 0.9 x 0.9 x 3.0 mm, Scan time = 7:02 3.Dark Fluid/FLAIR-2 (fluid attenuating inversion recovery)Axial plane, Field of View = 230 mm2, Matrix = 256 x 256, TRITE/TI = 10,000199/2150 ms, 3 mm slice thickness, no inter-slice gap, 40 slices, Voxel size = 0.9 x 0.9 x 3.0 mm, Scan time = 7:02 4.Proton Density/T2 weightedAxial plane, Field of view = 230 mm2, Matrix = 256 x 256, TR/TE1/TE2 = 6,000/18/105 ms, 3 mm slice thickness, no inter-slice gap, 40 slices, Voxel size = 0.9 x 0.9 x 3.0 mm, Scan time = 4:50 5.Post-Gd T1 weighted*. Spin Echo T1 series, Field of View = 230 mm2, Matrix = 256 x 256, TR/TE = 760/12 ms, 3 mm slice thickness, no inter-slice gap, 40 slices, Scan time = 3:18*A Gadolinium-based contrast agent (Magnevist) will be injected (IV) at 0.1 mmol/kg of patient weight, 5 minutes prior to post-Gd T1 image acquisition. The injection will be at a rate of 2 ml/s and will be performed using a power injector. The estimated total time for each MRI will be approximately 30 minutes per study. All MRI images will be read for incidental findings by a credentialed neurologist or radiologist, and image files will be stored in anonymized DICOM format in the Pl's office. To calculate BPF, we will perform an automated analysis using SIENA (Structural Image Evaluation, using Normalisation of Atrophy, University of Oxford)7980. In SIENA, brain tissue is segmented from non-brain tissue, and brain surface area and brain volume are measured. BPF is then calculated as a ratio of brain parenchymal tissue to total volume within the brain surface contour. Change in volume between two time points determines the rate of atrophy. The possibility for bias in analyzing the scans will be minimized since SIENA is automated, and since MRIs will be batched and analyzed in groups of 5. Interpretation of Results. Rates of atrophy will be calculated as percent change in BPF per subject per study period (on-lithium vs. off-lithium). Results will then be compared using a T-test for paired data in which percent change during the lithium-treatment period will be compared to percent change during the off-lithium period. A significant difference in the percent change in BPF favoring the lithium-treatment period will be interpreted as evidence of lithium's effect on decreasing the rate of atrophy on axonal integrity. Interested offers shall e-mail contract specialist, Connie Ganier at connie.ganier@va.gov no later than Noon EST on 6 August 2014.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/VA/BiVAMC521/BiVAMC521/VA24714I1255/listing.html)
 

Document(s)

Attachment
 

File Name: VA247-14-I-1255 VA247-14-I-1255_1.docx (https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=1538704&FileName=VA247-14-I-1255-000.docx)

Link: https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=1538704&FileName=VA247-14-I-1255-000.docx

 

Note: If links are broken, refer to Point of Contact above or contact the FBO Help Desk at 877-472-3779.
 

Place of Performance

Address: Birmingham VA Medical Center;700 S. 19th Street;Birmingham, AL

Zip Code: 35233
 

Record

SN03445469-W 20140802/140801000026-07a85f35435b02d91c5cacc766123bbe (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |